Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

GDS_investing Feb. 24 at 6:07 PM

$VTVT on the move good volume today very low float need to cross 44 next targets 56 and 84$ !! long and strong $VTVT

0 · Reply

ShadowClaw Feb. 24 at 5:54 PM

-@SqueezeSharkie is on a completely different level, easily ahead of 90% of traders here. -If you’re serious about leveling up, you should already be following him. It’s free, takes two seconds, and you won’t regret it💎 $SILO $MAX $VTVT $SGMO •

1 · Reply

JimJames Feb. 24 at 5:36 PM

$VTVT

0 · Reply

km1663 Feb. 24 at 4:47 PM

$VTVT Up13% and on strong volume!

0 · Reply

GDS_investing Feb. 24 at 3:18 PM

$VTVT You will sell a diamond for the price of glass, buy it

0 · Reply

GDS_investing Feb. 24 at 3:13 PM

$VTVT good volume today so far long !

0 · Reply

dcajic2 Feb. 23 at 8:35 PM

$VTVT shorted and trying to find as many shorts as possible. My guess they will print nothing regarding presentation on Thursday. They will be mum on news going into second half.

0 · Reply

dcajic2 Feb. 23 at 4:48 PM

$VTVT keeping a small position and trying to find some short. Should have sold all my king position. Last week. Just a company that will not have results of anything for another 5 to 20 Months

0 · Reply

dcajic2 Feb. 20 at 5:40 PM

$VTVT wait to buy under $30. Reality is no real news until after July. 5 months without any real news.

0 · Reply

LongBallBarn Feb. 20 at 2:55 PM

$VTVT Approval =

0 · Reply

vTv Therapeutics to Participate in Upcoming Investor Conferences

Feb 2, 2026, 8:00 AM EST - 22 days ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

Dec 18, 2025, 4:05 PM EST - 2 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Nov 6, 2025, 4:15 PM EST - 3 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 9, 2025, 8:00 AM EDT - 4 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Sep 15, 2025, 8:00 AM EDT - 5 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 3, 2025, 4:57 PM EDT - 6 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 6 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 6 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Aug 12, 2025, 4:15 PM EDT - 7 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 7 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 7, 2025, 8:00 AM EDT - 7 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 9 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 10 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 10 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 10 months ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 1:59 PM EDT - 1 year ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 2 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Mar 6, 2023, 5:56 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 8:02 AM EST - 3 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Feb 27, 2023, 8:02 AM EST - 3 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 1, 2023, 5:00 PM EST - 3 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

GDS_investing Feb. 24 at 6:07 PM

$VTVT on the move good volume today very low float need to cross 44 next targets 56 and 84$ !! long and strong $VTVT

0 · Reply

ShadowClaw Feb. 24 at 5:54 PM

1 · Reply

JimJames Feb. 24 at 5:36 PM

$VTVT

0 · Reply

km1663 Feb. 24 at 4:47 PM

$VTVT Up13% and on strong volume!

0 · Reply

GDS_investing Feb. 24 at 3:18 PM

$VTVT You will sell a diamond for the price of glass, buy it

0 · Reply

GDS_investing Feb. 24 at 3:13 PM

$VTVT good volume today so far long !

0 · Reply

dcajic2 Feb. 23 at 8:35 PM

$VTVT shorted and trying to find as many shorts as possible. My guess they will print nothing regarding presentation on Thursday. They will be mum on news going into second half.

0 · Reply

dcajic2 Feb. 23 at 4:48 PM

$VTVT keeping a small position and trying to find some short. Should have sold all my king position. Last week. Just a company that will not have results of anything for another 5 to 20 Months

0 · Reply

dcajic2 Feb. 20 at 5:40 PM

$VTVT wait to buy under $30. Reality is no real news until after July. 5 months without any real news.

0 · Reply

LongBallBarn Feb. 20 at 2:55 PM

$VTVT Approval =

0 · Reply

dcajic2 Feb. 19 at 3:58 PM

$VTVT Where is management?

0 · Reply

dcajic2 Feb. 18 at 11:44 PM

$VTVT sold half. Will buy back around 33. Company lack news it will likely go back towards 30

0 · Reply

Bullfinch Feb. 18 at 9:18 PM

$VTVT https://ir.vtvtherapeutics.com/sec-filings/sec-filing/4/0001264519-26-000002

0 · Reply

Bullfinch Feb. 18 at 9:18 PM

$VTVT https://ir.vtvtherapeutics.com/sec-filings/sec-filing/4/0002069755-26-000003

0 · Reply

dcajic2 Feb. 18 at 5:55 PM

$VTVT Taking. A few off The table. Too big not too. This comoany has had issues with releasing any real news. It could be months before we hear anything.

0 · Reply

GDS_investing Feb. 18 at 5:34 PM

$ZIM $VTVT on the move all for long $ZIM = 35$ $VTVT = 56$ then 84$

0 · Reply

LongBallBarn Feb. 18 at 5:26 PM

$VTVT

0 · Reply

dcajic2 Feb. 18 at 5:06 PM

$VTVT getting interesting but we need news now.

0 · Reply

GDS_investing Feb. 18 at 4:28 PM

$VTVT

0 · Reply

LateCycleLogic Feb. 18 at 3:40 PM

$VTVT vTv Therapeutics is an early-stage biotech with long development timelines. Pipeline optionality exists but dilution risk remains high. Data quality drives valuation resets.

1 · Reply

dcajic2 Feb. 18 at 3:19 PM

$VTVT bring on the news.

0 · Reply

km1663 Feb. 17 at 9:08 PM

$VTVT +10% gain on better than average volume day!

0 · Reply

Market Cap	135.08M
Revenue (ttm)	1.02M
Net Income (ttm)	-18.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,809.80%
Debt to Equity Ratio	0.00

Volume	54,600
Avg Vol	20,996
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	44%
Beta	0.50
Analysts	Strong Sell
Price Target	$51.20